TABLE 5.
Relative Risk of Mortality for Stroke Patients Receiving Selfotel versus Placebo, by Stroke Severity
| Indication | Selfotel, % (n/N) | Placebo, % (n/N) | Relative Risk | CI |
|---|---|---|---|---|
| All deaths | ||||
| All patients | 22.1 (62/280)* | 17.1 (49/286) | 1.292 | (0.923, 1.809) |
| Severe patients | 30.5 (57/187) | 21.6 (40/185) | 1.410 | (0.994, 1.999) |
| Mild/moderate patients | 4.3 (4/92) | 8.9 (9/101) | 0.488 | (0.156, 1.531) |
| Deaths by day 8 | ||||
| All patients | 11.4 (32/280)* | 5.9 (17/286) | 1.923 | (1.093, 3.382) |
| Severe patients | 16.6 (31/187) | 9.2 (17/185) | 1.804 | (1.035, 3.144) |
| Mild/moderate patients | 0.6 (0/92) | 0.0 (0/101) |
*
Includes one Selfotel patient (patient 402 in protocol 10) who had no baseline stroke severity score and died on day 2.24
CI = confidence interval; n = number of patients dying; N = total number of patients.
From Davis et al. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 31:347–354. Copyright © 2000, Lippincott Williams and Wilkins. All rights reserved.